UNIVERSITY OF ALABAMA AT BIRMINGHAM

The FDA has granted Orphan Drug Designation to Mustang Bio's MB-101 CAR-T therapy for treating astrocytomas and glioblastoma, providing seven years of market exclusivity and development incentives.

The FDA has approved Darmiyan's 7-year post-market surveillance study for BrainSee, the first FDA-approved AI-powered tool that predicts Alzheimer's disease progression in patients with mild cognitive impairment.

GeoVax has strengthened its Gedeptin therapy platform with newly allowed patent claims covering the synergistic combination of gene therapy with radiation for treating various solid tumors.

City of Hope has initiated a phase 1/2 clinical trial investigating whether denosumab, an FDA-approved osteoporosis medication, can protect and regenerate insulin-producing beta cells in early-stage type 1 diabetes patients.

UAB researchers initiate NIH-funded clinical trial comparing three diabetes treatments - Metformin, Insulin Glargine, and experimental drug Dorzagliatin - to evaluate their effectiveness on nocturnal blood sugar control.

The University of Alabama at Birmingham (UAB) is conducting a clinical trial to evaluate a novel on-demand PrEP rectal douche.

Leading cardiologists at ASPC Congress 2024 highlight the transformative role of AI and advanced imaging techniques in early detection of cardiovascular risks, particularly through coronary computed tomography angiography.

A new review highlights the potential of cell-based therapies for heart failure, which accounts for 13% of global deaths, noting that half of patients die within five years.

Researchers at UAB have identified a 36-gene score, UAB36, that predicts resistance to anti-cancer drugs in various cancer cell lines.

Researchers have identified a 36-gene signature, UAB36, that predicts resistance to anti-cancer drugs across various cancer cell lines, enhancing personalized medicine approaches.